Tenon Medical (TNON) Expected to Post Quarterly Earnings on Thursday

Tenon Medical (NASDAQ:TNON) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Tenon Medical to announce earnings of ($4.2250) per share and revenue of $1.55 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Tenon Medical (NASDAQ:TNON) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($12.35) EPS for the quarter, missing the consensus estimate of ($8.40) by ($3.95). The business had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.54 million. Tenon Medical had a negative net margin of 257.85% and a negative return on equity of 907.60%.

Tenon Medical Stock Performance

Shares of TNON opened at $1.75 on Tuesday. The business’s 50-day moving average is $3.21 and its two-hundred day moving average is $16.20. The company has a market capitalization of $4.71 million, a P/E ratio of -0.04 and a beta of 1.43. Tenon Medical has a fifty-two week low of $1.57 and a fifty-two week high of $45.50.

Insider Transactions at Tenon Medical

In related news, major shareholder Financial Lp Hrt sold 65,582 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $5.56, for a total transaction of $364,635.92. Following the sale, the insider owned 15,839 shares in the company, valued at approximately $88,064.84. This trade represents a 80.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have acquired 129,945 shares of company stock worth $500,468 and have sold 136,599 shares worth $605,467. Company insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

TNON has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Tenon Medical in a research note on Thursday, October 15th. Wall Street Zen cut Tenon Medical from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

About Tenon Medical

Tenon Medical, Inc (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain.

The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.

Tenon Medical was founded in 2014 and is based in Los Gatos, California.